Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 24;22(2):191.
doi: 10.3390/molecules22020191.

Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years

Affiliations
Free PMC article
Review

Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years

Alessandro Federico et al. Molecules. .
Free PMC article

Abstract

Silymarin is the extract of Silybum marianum, or milk thistle, and its major active compound is silybin, which has a remarkable biological effect. It is used in different liver disorders, particularly chronic liver diseases, cirrhosis and hepatocellular carcinoma, because of its antioxidant, anti-inflammatory and antifibrotic power. Indeed, the anti-oxidant and anti-inflammatory effect of silymarin is oriented towards the reduction of virus-related liver damages through inflammatory cascade softening and immune system modulation. It also has a direct antiviral effect associated with its intravenous administration in hepatitis C virus infection. With respect to alcohol abuse, silymarin is able to increase cellular vitality and to reduce both lipid peroxidation and cellular necrosis. Furthermore, silymarin/silybin use has important biological effects in non-alcoholic fatty liver disease. These substances antagonize the progression of non-alcoholic fatty liver disease, by intervening in various therapeutic targets: oxidative stress, insulin resistance, liver fat accumulation and mitochondrial dysfunction. Silymarin is also used in liver cirrhosis and hepatocellular carcinoma that represent common end stages of different hepatopathies by modulating different molecular patterns. Therefore, the aim of this review is to examine scientific studies concerning the effects derived from silymarin/silybin use in chronic liver diseases, cirrhosis and hepatocellular carcinoma.

Keywords: alcoholic liver disease; antioxidants; hepatocellular carcinoma; non-alcoholic fatty liver disease; silybin; silymarin; viral hepatitis.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Different therapeutic activities of silymarin. IL-1/6: interleukin1/6; TNF-α: tumor necrosis factor-α; IFN-γ: interferon-γ; GM-CSF: granulocyte-macrophage colony stimulating factor; MAPK: mitogen-activated protein kinase; Bax: bcl-2-like protein 4; Bcl-2: B-cell lymphoma 2; IGF: insuline-like growth factor; α-SMA: α-smooth muscle actin; TGF-β: transforming growth factor-β; HSP: heat shock proteins; PPAR-γ: peroxisome proliferator-activated receptor γ; PI3K: phosphatidylinositol-4,5-bisphosphate 3-kinase; Akt: protein kinase B; HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A; GLUT 4: glucose transporter type 4.
Figure 2
Figure 2
Therapeutic targets of silymarin in non-alcoholic fatty liver disease. TG: triglycerides; ROS: Reactive oxygen species; IL-1/6/8: interleukin-1/6/8; TNF-α: tumor necrosis factor alpha; INF-γ: interferon-gamma; TGF-β: transforming growth factor-beta; NF-κB: nuclear factor kappaB; FF: free fat; NAFL: non-alcoholic fatty liver; NASH: non-alcoholic steatohepatitis; HCC: hepatocellular carcinoma; PPAR-γ: peroxisome proliferator-activated receptor gamma; SREBP: sterol regulatory element-binding proteins; Apo B: apolipoprotein B; MTP: microsomal triglyceride transfer protein.

Similar articles

See all similar articles

Cited by 41 articles

See all "Cited by" articles

References

    1. Pradhan S.C., Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Ind. J. Med. Res. 2006;124:491–504. - PubMed
    1. Schadewaldt H. The history of Silymarin. Contribution to the history of liver therapy. Die Med. Welt. 1969;20:902–914. - PubMed
    1. Kim N.C., Graf T.N., Sparacino C.M., Wani M.C., Wall M.E. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum) Org. Biomol. Chem. 2003;1:1684–1689. doi: 10.1039/b300099k. - DOI - PubMed
    1. Loguercio C., Festi D. Silybin and the liver: From basic research to clinical practice. World J. Gastroenterol. 2011;17:2288–2301. doi: 10.3748/wjg.v17.i18.2288. - DOI - PMC - PubMed
    1. Crocenzi F.A., Roma M.G. Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr. Med. Chem. 2006;13:1055–1074. doi: 10.2174/092986706776360950. - DOI - PubMed

MeSH terms

Feedback